# NaturalShrimp Inc: financial statements, quarterly

SHMP · OTC · CIK 1465470 · [Consumer staples](/sectors/consumer-staples.md) · fiscal year ends Mar 31

Pages: [Overview](/companies/shmp.md) · [Financials](/companies/shmp/financials.md) · [Filings](/companies/shmp/filings.md) · [Insiders](/companies/shmp/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/shmp/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2022-12-31) | Q4 FY2023 (2023-03-31) | Q1 FY2024 (2023-06-30) | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-30) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.1](/filings/0001493152-24-006697.md) | [0.1 d](/filings/0001493152-24-028214.md) | [0.2](/filings/0001493152-24-032357.md) | [0.1](/filings/0001641172-25-025047.md) | [0.1](/filings/0001641172-25-027039.md) | [0.1 d](/filings/0001493152-24-028214.md) | [0.0](/filings/0001493152-24-032357.md) | [0.1](/filings/0001641172-25-025047.md) | [0.1](/filings/0001641172-25-027039.md) | [0.0 d](/filings/0001493152-25-020857.md) | [0.0](/filings/0001493152-26-007000.md) | [0.1 d](/filings/0001493152-26-026574.md) |
| Cost of revenue | $m | not reported | not reported | [0.0](/filings/0001493152-24-032357.md) | [0.1](/filings/0001641172-25-025047.md) | [0.0](/filings/0001641172-25-027039.md) | [0.0 d](/filings/0001493152-24-028214.md) | [0.0](/filings/0001493152-24-032357.md) | [0.1](/filings/0001641172-25-025047.md) | [0.0](/filings/0001641172-25-027039.md) | [0.0 d](/filings/0001493152-26-034187.md) | [0.0](/filings/0001493152-26-007000.md) | [0.1 d](/filings/0001493152-26-026574.md) |
| Gross profit | $m | [0.1](/filings/0001493152-24-006697.md) | [(0.1) d](/filings/0001493152-24-028214.md) | [0.2](/filings/0001493152-24-032357.md) | [0.0](/filings/0001641172-25-025047.md) | [0.1](/filings/0001641172-25-027039.md) | [0.1 d](/filings/0001493152-24-028214.md) | [0.0](/filings/0001493152-24-032357.md) | [0.0](/filings/0001641172-25-025047.md) | [0.0](/filings/0001641172-25-027039.md) | [0.0 d](/filings/0001493152-26-034187.md) | [0.0](/filings/0001493152-26-007000.md) | [0.0 d](/filings/0001493152-26-026574.md) |
| Research and development | $m | [0.0](/filings/0001493152-24-006697.md) | [0.0 d](/filings/0001493152-24-028214.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(3.1)](/filings/0001493152-24-006697.md) | [(2.7) d](/filings/0001493152-24-028214.md) | [(2.3)](/filings/0001493152-24-032357.md) | [(3.4)](/filings/0001641172-25-025047.md) | [(2.3)](/filings/0001641172-25-027039.md) | [(2.6) d](/filings/0001493152-24-028214.md) | [(2.1)](/filings/0001493152-24-032357.md) | [(1.2)](/filings/0001641172-25-025047.md) | [(2.0)](/filings/0001641172-25-027039.md) | [(1.7) d](/filings/0001493152-26-034187.md) | [(2.1)](/filings/0001493152-26-007000.md) | [(1.2) d](/filings/0001493152-26-026574.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [15.2](/filings/0001493152-24-006697.md) | [(4.4) d](/filings/0001493152-24-028214.md) | [(2.3)](/filings/0001641172-25-027039.md) | [(2.6)](/filings/0001641172-25-027039.md) | [(5.4)](/filings/0001641172-25-027039.md) | [(5.3) d](/filings/0001493152-24-028214.md) | [(2.8)](/filings/0001493152-26-030232.md) | [(1.1)](/filings/0001493152-26-030232.md) | [(2.4)](/filings/0001493152-26-030232.md) | [(4.4) d](/filings/0001493152-26-034187.md) | [(2.8)](/filings/0001493152-26-007000.md) | [(1.1) d](/filings/0001493152-26-026574.md) |
| Diluted EPS | $ per share | [0.01](/filings/0001493152-24-006697.md) | not reported | [0.00](/filings/0001493152-24-032357.md) | [0.00](/filings/0001641172-25-025047.md) | [(0.01)](/filings/0001641172-25-027039.md) | not reported | [0.00](/filings/0001493152-24-032357.md) | [0.00](/filings/0001641172-25-025047.md) | [0.00](/filings/0001641172-25-027039.md) | not reported | [0.00](/filings/0001493152-26-007000.md) | not reported |
| Basic EPS | $ per share | [0.02](/filings/0001493152-24-006697.md) | not reported | [0.00](/filings/0001493152-24-032357.md) | [0.00](/filings/0001641172-25-025047.md) | [(0.01)](/filings/0001641172-25-027039.md) | not reported | [0.00](/filings/0001493152-24-032357.md) | [0.00](/filings/0001641172-25-025047.md) | [0.00](/filings/0001641172-25-027039.md) | not reported | [0.00](/filings/0001493152-26-007000.md) | not reported |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2023 (2022-09-30) | Q3 FY2023 (2022-12-31) | FY2023 (2023-03-31) | Q1 FY2024 (2023-06-30) | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | FY2025 (2025-03-30) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [0.6](/filings/0001493152-22-031945.md) | [0.1](/filings/0001493152-23-005319.md) | [0.2](/filings/0001493152-24-028214.md) | [0.1](/filings/0001493152-23-029450.md) | [0.0](/filings/0001493152-23-042141.md) | [0.0](/filings/0001493152-24-006697.md) | [0.1](/filings/0001641172-25-027039.md) | [0.0](/filings/0001493152-24-032357.md) | [0.0](/filings/0001641172-25-025047.md) | [0.0](/filings/0001641172-25-027039.md) | [0.1](/filings/0001493152-25-020857.md) | [0.0](/filings/0001493152-26-045331.md) |
| Current assets | $m | [5.4](/filings/0001493152-22-031945.md) | [0.9](/filings/0001493152-23-005319.md) | [1.9](/filings/0001493152-24-028214.md) | [1.8](/filings/0001493152-23-029450.md) | [0.3](/filings/0001493152-23-042141.md) | [0.3](/filings/0001493152-24-006697.md) | [0.4](/filings/0001641172-25-027039.md) | [0.2](/filings/0001493152-24-032357.md) | [0.3](/filings/0001641172-25-025047.md) | [0.3](/filings/0001641172-25-027039.md) | [0.3](/filings/0001493152-25-020857.md) | [0.0](/filings/0001493152-26-045331.md) |
| Total assets | $m | [37.0](/filings/0001493152-22-031945.md) | [32.3](/filings/0001493152-23-005319.md) | [32.6](/filings/0001493152-24-028214.md) | [31.7](/filings/0001493152-23-029450.md) | [29.4](/filings/0001493152-23-042141.md) | [28.5](/filings/0001493152-24-006697.md) | [27.7](/filings/0001641172-25-027039.md) | [26.8](/filings/0001493152-24-032357.md) | [25.9](/filings/0001641172-25-025047.md) | [25.0](/filings/0001641172-25-027039.md) | [24.3](/filings/0001493152-25-020857.md) | [0.0](/filings/0001493152-26-045331.md) |
| Current liabilities | $m | [43.8](/filings/0001493152-22-031945.md) | [9.1](/filings/0001493152-23-005319.md) | [11.2](/filings/0001493152-24-028214.md) | [10.6](/filings/0001493152-23-029450.md) | [10.6](/filings/0001493152-23-042141.md) | [10.7](/filings/0001493152-24-006697.md) | [38.5](/filings/0001641172-25-027039.md) | [39.7](/filings/0001493152-24-032357.md) | [39.6](/filings/0001641172-25-025047.md) | [41.1](/filings/0001641172-25-027039.md) | [45.0](/filings/0001493152-25-020857.md) | [11.4](/filings/0001493152-26-045331.md) |
| Total liabilities | $m | [50.8](/filings/0001493152-22-031945.md) | [29.6](/filings/0001493152-23-005319.md) | [32.7](/filings/0001493152-24-028214.md) | [32.6](/filings/0001493152-23-029450.md) | [32.4](/filings/0001493152-23-042141.md) | [35.4](/filings/0001493152-24-006697.md) | [38.6](/filings/0001641172-25-027039.md) | [39.7](/filings/0001493152-24-032357.md) | [39.6](/filings/0001641172-25-025047.md) | [41.1](/filings/0001641172-25-027039.md) | [45.0](/filings/0001493152-25-020857.md) | [11.4](/filings/0001493152-26-045331.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(59.2)](/filings/0001493152-22-031945.md) | [(42.9)](/filings/0001493152-23-005319.md) | [(45.7)](/filings/0001641172-25-027039.md) | [(46.3)](/filings/0001641172-25-027039.md) | [(48.5)](/filings/0001641172-25-027039.md) | [(52.7)](/filings/0001641172-25-027039.md) | [(56.9)](/filings/0001493152-26-034187.md) | [(59.2)](/filings/0001493152-26-030232.md) | [(60.1)](/filings/0001493152-26-030232.md) | [(62.5)](/filings/0001493152-26-030232.md) | [(67.1)](/filings/0001493152-26-034187.md) | [(55.4)](/filings/0001493152-26-045331.md) |

- Cash and equivalents: us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2022-12-31) | Q4 FY2023 (2023-03-31) | Q1 FY2024 (2023-06-30) | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-30) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(254) d](/filings/0001493152-24-006697.md) | [(1,974) d](/filings/0001493152-24-028214.md) | [(1,401)](/filings/0001493152-24-032357.md) | [(800) d](/filings/0001641172-25-025047.md) | [(657) d](/filings/0001641172-25-027039.md) | [(1,017) d](/filings/0001493152-24-028214.md) | [(806)](/filings/0001493152-24-032357.md) | [(750) d](/filings/0001641172-25-025047.md) | [(555) d](/filings/0001493152-26-030232.md) | [(1,781) d](/filings/0001493152-26-034187.md) | [(806)](/filings/0001493152-26-007000.md) | [(750) d](/filings/0001493152-26-026574.md) |
| Capital expenditure | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported

## Shares

| Line item | Unit | Q3 FY2012 (2011-12-31) | Q3 FY2022 (2021-12-31) | Q1 FY2023 (2022-06-30) | Q2 FY2023 (2022-09-30) | Q3 FY2023 (2022-12-31) | Q1 FY2024 (2023-06-30) | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q1 FY2026 (2025-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [97.0](/filings/0001002014-12-000063.md) | [636](/filings/0001493152-23-005319.md) | [666](/filings/0001493152-23-029450.md) | [732](/filings/0001493152-23-042141.md) | [1,629](/filings/0001493152-24-006697.md) | [840](/filings/0001493152-24-032357.md) | [898](/filings/0001641172-25-025047.md) | [938](/filings/0001641172-25-027039.md) | [1,167](/filings/0001493152-24-032357.md) | [1,136](/filings/0001641172-25-025047.md) | [1,223](/filings/0001641172-25-027039.md) | [1,167](/filings/0001493152-26-007000.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 1,277,546,746 at 2026-08-09, from the cover of the [10-Q filed 2026-10-01](/filings/0001493152-26-045331.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:40 ET. No prices; not investment advice.